The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Antiretroviral Treatment of Adult HIV Infection: 2014 Recommendations of the International Antiviral Society–USA Panel
Abstract
IMPORTANCE New data and antiretroviral regimens expand treatment choices in resource-rich settings and warrant an update of recommendations to treat adults infected with human immunodeficiency virus (HIV). OBJECTIVE To provide updated treatment recommendations for adults with HIV, emphasizing when to start treatment; what treatment to start; the use of laboratory monitoring tools; and managing treatment failure, switches, and simplification. DATA SOURCES, STUDY SELECTION, AND DATA SYNTHESIS An International Antiviral Society-USA panel of experts in HIV research and patient care considered previous data and reviewed new data since the 2012 update with literature searches in PubMed and EMBASE through June 2014. Recommendations and ratings were based on the quality of evidence and consensus. RESULTS Antiretroviral therapy is recommended for all adults with HIV infection. Evidence for benefits of treatment and quality of available data increase at lower CD4 cell counts. Recommended initial regimens include 2 nucleoside reverse transcriptase inhibitors (NRTIs; abacavir/lamivudine or tenofovir disoproxil furnarate/emtricitabine) and a third single or boosted drug, which should be an integrase strand transfer inhibitor (dolutegravir, elvitegravir, or raltegravir), a nonnucleoside reverse transcriptase inhibitor (efavirenz or rilpivirine) or a boosted protease inhibitor (darurlavir or atazanavir). Alternative regimens are available. Boosted protease inhibitor monotherapy is generally not recommended, but NRTI-sparing approaches may be considered. New guidance for optimal timing of monitoring of laboratory parameters is provided. Suspected treatment failure warrants rapid confirmation, performance of resistance testing while the patient is receiving the failing regimen, and evaluation of reasons for failure before consideration of switching therapy. Regimen switches for adverse effects, convenience, or to reduce costs should not jeopardize antiretroviral potency. CONCLUSIONS AND RELEVANCE After confirmed diagnosis of HIV infection, antiretroviral therapy should be initiated in all individuals who are willing and ready to start treatment. Regimens should be selected or changed based on resistance test results with consideration of dosing frequency, pill burden, adverse toxic effect profiles, comorbidities, and drug interactions
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sáez-Cirión, A., Bacchus, C., Hocqueloux, L., Avettand-Fenoel, V., Girault, I., Lecuroux, C., Potard, V., Versmisse, P., Melard, A., Prazuck, T., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003211 · Cited by 1,011
Tanser, F., Bärnighausen, T., Grapsa, E., Zaidi, J., & Newell, M.-L. (2013) · Science · doi:10.1126/science.1228160 · Cited by 796
Absence of Detectable HIV-1 Viremia after Treatment Cessation in an Infant
Persaud, D., Gay, H., Ziemniak, C., Chen, Y. H., Piatak, M., Chun, T.-W., Strain, M., Richman, D., & Luzuriaga, K. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302976 · Cited by 581
Hirsch, M. S., Günthard, H. F., Schapiro, J. M., Brun‐Vézinet, F., Clotet, B., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Mellors, J. W., Pillay, D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/589297 · Cited by 573
Self-citationMocroft, A., Kirk, O., Reiss, P., De Wit, S., Sedlacek, D., Beniowski, M., Gatell, J., Phillips, A. N., Ledergerber, B., & Lundgren, J. D. (2010) · AIDS · doi:10.1097/qad.0b013e328339fe53 · Cited by 406
Self-citationRodger, A. J., Lodwick, R., Schechter, M., Deeks, S., Amin, J., Gilson, R., Paredes, R., Bakowska, E., Engsig, F. N., & Phillips, A. (2013) · AIDS · doi:10.1097/qad.0b013e32835cae9c · Cited by 372
Laprise, C., de Pokomandy, A., Baril, J.-G., Dufresne, S., & Trottier, H. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit529 · Cited by 173
Reynes, J., Trinh, R. N., Pulido, F., Soto-Malave, R., Gathe, J., Qaqish, R. B., Tian, M., Fredrick, L. M., Podsadecki, T. J., Norton, M., et al. (2012) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2011.0275 · Cited by 151
Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events
Monforte, A. D., Reiss, P., Ryom, L., El-Sadr, W. M., Dabis, F., Wit, S. D., Worm, S. W., Law, M. G., Weber, R. K., Kirk, O., et al. (2013) · AIDS · doi:10.1097/qad.0b013e32835b2ef1 · Cited by 108
Self-citationGonzález‐Serna, A., Min, J. E., Woods, C. K., Chan, D., Lima, V., Montaner, J. S. G., Harrigan, P. R., & Swenson, L. C. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu019 · Cited by 101
Hamada, Y., Nishijima, T., Watanabe, K., Komatsu, H., Tsukada, K., Teruya, K., Gatanaga, H., Kikuchi, Y., & Oka, S. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis621 · Cited by 92
Li, J. Z., Gallien, S., Ribaudo, H. J., Heisey, A., Bangsberg, D. R., & Kuritzkes, D. R. (2013) · AIDS · doi:10.1097/qad.0000000000000123 · Cited by 89
Maggiolo, F., Callegaro, A., Cologni, G., Bernardini, C., Velenti, D., Gregis, G., Quinzan, G., Soavi, L., Iannotti, N., Malfatto, E. N., et al. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182567a57 · Cited by 88
Wada, N., Jacobson, L. P., Cohen, M. H., et al. (2013) · AIDS · doi:10.1097/qad.0000000000000078 · Cited by 86
Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations
Soliman, E. Z., Lundgren, J. D., Roediger, M. P., Duprez, D. A., Temesgen, Z., Bickel, M., Shlay, J. C., Somboonwit, C., Reiss, P., Stein, J. H., et al. (2010) · AIDS · doi:10.1097/qad.0b013e328341dcc0 · Cited by 73
Self-citation
Cited by
Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., et al. (2021) · Stroke · doi:10.1161/str.0000000000000375 · Cited by 3,237
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
The INSIGHT START Study Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506816 · Cited by 2,798
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784
Self-citationDefective proviruses rapidly accumulate during acute HIV-1 infection
Bruner, K. M., Murray, A. J., Pollack, R. A., Soliman, M. G., Laskey, S. B., Capoferri, A. A., Lai, J., Strain, M. C., Lada, S. M., Hoh, R., et al. (2016) · Nature Medicine · doi:10.1038/nm.4156 · Cited by 737
Günthard, H. F., Saag, M. S., Benson, C. A., del Rio, C., Eron, J. J., Gallant, J. E., Hoy, J. F., Mugavero, M. J., Sax, P. E., Thompson, M. A., et al. (2016) · JAMA · doi:10.1001/jama.2016.8900 · Cited by 656
Self-citation
Metadata
- Authors
- Günthard, H. F., Aberg, J. A., Eron, J. J., Hoy, J. F., Telenti, A., Benson, C. A., Burger, D. M., Cahn, P., Gallant, J. E., Glesby, M. J., Reiss, P., Saag, M. S., Thomas, D. L., Jacobsen, D. M., & Volberding, P. A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2014-07-23
- Volume
- 312
- Issue
- 4
- Pages
- 410
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4240243247
- Cited by
- 449
- References
- 16
- FWCI
- 67.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.